Global Regulatory Frameworks for GVP
EMA
FDA
Health Canada
MHRA
Yellow Card
WHO
ICH
Guidelines
The European Medicines Agency publishes Good Pharmacovigilance Practice modules that set out requirements for pharmacovigilance systems in the EU. Module I covers Pharmacovigilance systems and their quality systems. Module II covers Pharmacovigilance system master file. Module V covers Risk management systems. Module VI covers Collection, management and submission of reports. Module VIII covers Post authorization safety studies. Module IX covers Signal management. Module XV covers Safety communication. Module XVI covers Risk minimization measures.
The FDA regulates pharmacovigilance through requirements for postmarketing reporting of adverse drug experiences. 21 CFR 314.80 covers postmarketing reporting of adverse drug experiences. 21 CFR 314.98 covers postmarketing reports for approved applications. 21 CFR 600.80 covers biological products. Safety reporting timelines require 15 days for serious unexpected events. Periodic safety reports are required at defined intervals.
Health Canada regulates pharmacovigilance through the Food and Drug Regulations and the Canada Vigilance Program. The Food and Drug Regulations cover post market reporting. The Canada Vigilance Program covers adverse reaction reporting. Risk management plans are required for certain products.
The MHRA regulates pharmacovigilance in the United Kingdom through UK specific requirements. UK pharmacovigilance requirements post Brexit include the Yellow Card Scheme for adverse reaction reporting, risk management plans, and periodic safety update reports.
The World Health Organization publishes pharmacovigilance guidelines that serve as an international reference. This includes the WHO Programme for International Drug Monitoring and guidelines on safety monitoring of medicinal products.
The International Council for Harmonisation publishes guidelines that support pharmacovigilance activities. ICH E2A covers Clinical safety data management. ICH E2B covers Data elements for transmission of individual case safety reports. ICH E2C covers Periodic safety update reports. ICH E2D covers Post approval safety data management. ICH E2E covers Pharmacovigilance planning.
We audit the overall pharmacovigilance system to verify that it meets regulatory requirements. This includes quality system for pharmacovigilance, organizational structure and responsibilities, personnel qualifications and training, standard operating procedures, documentation and record keeping, and compliance monitoring and CAPA.
We audit the Pharmacovigilance System Master File to verify that it is complete and current. This includes PSMF content and maintenance, annexes and supporting documents, change control and version management, and availability to authorities upon request.
We audit the processing and reporting of individual case safety reports. This includes case intake and data entry, case processing and medical review, coding and MedDRA terminology, follow up procedures, submission timelines and compliance, and electronic submission gateway compliance.
We audit signal detection and management processes to verify that safety signals are identified and managed appropriately. This includes signal detection methodologies, signal validation and prioritization, signal assessment and evaluation, signal management documentation, and communication of safety signals.
We audit risk management plans to verify that they meet regulatory requirements. This includes RMP content and updates, safety specifications, pharmacovigilance plans, risk minimization measures, and effectiveness evaluation.
We audit periodic safety reports to verify that they are complete and submitted on time. This includes PSUR/PBRER content and format, data analysis and benefit risk assessment, submission timelines, and regulatory authority responses.
We audit post authorization safety studies to verify that they are conducted according to protocol and regulatory requirements. This includes PASS protocol and design, study conduct and monitoring, data analysis and reporting, and publication and communication.
We audit pharmacovigilance service providers to verify that they meet regulatory requirements. This includes PV service provider qualification, quality agreements and responsibilities, subcontractor management, and oversight and performance monitoring.
We audit the technology platforms used for signal detection and safety data management. This includes safety database validation, signal detection software validation, data mining methodologies, and access controls and audit trails.
We serve marketing authorization holders, pharmaceutical companies, biotechnology companies, pharmacovigilance service providers, contract research organizations, medical device companies, vaccines manufacturers, and generic drug companies.
| Phase | Activities | Output |
|---|---|---|
| Planning | Scope, PV system review | Audit plan |
| Document review | SOPs, PSMF, procedures | Pre audit analysis |
| On site | Interviews, system review | Working notes |
| Case review | ICSR sampling, data verification | Findings |
| Close out | Classification and CAPA discussion | Draft findings |
| Report | Final report with prioritized actions | Audit report |
| Follow up | CAPA verification and closure | Closure letter |
You cannot copy content of this page
